Kenvue is expected to announce its third-quarter results by early November, and analysts expect a notable decline in earnings ...

For over a decade, and as recently as August, FDA has fully evaluated the emerging scientific evidence and repeatedly ...

“For over a decade — and as recently as August — FDA has fully evaluated the emerging scientific evidence and repeatedly ...

Kenvue urged U.S. regulators to deny a request warning against Tylenol’s use during pregnancy, laying out the most detailed ...

Kenvue has urged U.S. regulators to reject a request seeking autism warning label on its popular over-the-counter pain ...

Shares of Kenvue fell 13% Thursday to $14.11, its lowest finish since the consumer healthcare firm spun off from Johnson & ...

A potential legal headache for consumer healthcare giant Kenvue ( KVUE 8.36%) was causing pain for investors on Thursday.

After popular pain med Tylenol came under fire from officials in the Trump administration for an alleged link to autism if ...

Kenvue, the maker of Tylenol, is urging U.S. health regulators not to add an autism warning label to it and other ...

On Oct. 17, Kenvue filed a response to the Citizen Petition, arguing against the need to add a pregnancy/autism risk warning ...

Explore Kenvue Inc. (NYSE:KVUE) trends, dividends, and market activity among consumer stocks in S&P 500 today.

Kenvue, the maker of Tylenol, opposes proposed changes to the product's safety label regarding potential links to autism and ...